Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient preference-based phosphate binder therapy in haemodialysis patients
NL-OMON55060Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2022
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sevelamer carbonate, lanthanum carbonate and iron sucrose in hyperphosphatemia, chronic kidney disease (CKD) and end-stage kidney disease (ESKD) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Patient satisfaction with phosphate treatment. Started May 2022; status: recruiting.
02
Drugs
sevelamer carbonatelanthanum carbonateiron sucrose
03
Conditions
hyperphosphatemiachronic kidney disease (CKD)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on NL-OMON55060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55060.